Silence Therapeutics plc ADR (XRP2)

Overview

Silence Therapeutics plc stands at the forefront of biotechnology, concentrating on pioneering the development of novel molecules that incorporate short interfering ribonucleic acid (siRNA) technology. This innovative approach is designed to inhibit the expression of specific target genes that are implicated in a variety of conditions, focusing primarily on hematology, cardiovascular diseases, and rare diseases. With its headquarters nestled in London, United Kingdom, Silence Therapeutics plc was founded in 1994. Initially known as SR Pharma plc, the company underwent a rebranding to its current name in May 2007. Silence Therapeutics operates with a mission to harness the power of siRNA for therapeutic purposes, leveraging its mRNAi GalNAc Oligonucleotide Discovery platform. This technologically sophisticated platform enables the development of precision-engineered product candidates aimed at targeting disease-associated genes in the liver. In addition to its in-house development efforts, Silence Therapeutics has forged strategic collaboration agreements with several industry giants, including AstraZeneca PLC, Hansoh Pharmaceutical Group Company Limited, and Mallinckrodt Pharma IP Trading DAC. These partnerships are integral to the company's strategy, enhancing its capacity to discover, develop, and commercialize siRNA therapeutics across a broad range of diseases, including cardiovascular, renal, metabolic, respiratory, and complement-mediated disorders.

Products and Services

The portfolio of Silence Therapeutics is characterized by its diverse and innovative investigational products, primarily focusing on treating various diseases through siRNA technology:

• Zerlasiran (SLN360): This product candidate is currently in phase 2 clinical trial and targets cardiovascular disease associated with elevated lipoprotein(a) levels. By silencing specific genes, Zerlasiran aims to reduce the risk associated with high lipoprotein(a) levels, potentially offering a novel treatment option for individuals with cardiovascular conditions.
• Divesiran (SLN124): An siRNA molecule, Divesiran is in Phase I clinical trials and is designed for the treatment of genetic hematological conditions, including polycythemia vera. This product candidate represents Silence Therapeutics' commitment to addressing rare blood disorders through gene-silencing technology.
• SLN-COMP-1 and SLN-COMP-2: These are in the development stages for the treatment of complement-mediated diseases. While specific details about these product candidates are not extensively disclosed, they underscore the company's efforts to explore the therapeutic potential of siRNA in treating diseases arising from the complement system's dysfunction.
• SLN-HAN-1 and SLN-HAN-2: Details about SLN-HAN-1 and SLN-HAN-2 are limited, but their inclusion in Silence Therapeutics' pipeline illustrates the company's ongoing research activities aimed at harnessing siRNA technology for therapeutic interventions in various diseases.